Crescent Biopharma, Inc.

CBIO Healthcare Biotechnology

Crescent Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.8 million, up 108,340.0% from fiscal 2023. In the quarter to June 2026, revenue grew 1,038,900.0%, EPS grew 85.0% and free cash flow fell 7.04%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.84 0.64 −5.13%
Market cap
$463.6M
P/E
0.0×
Fwd P/E
−5.6×
Dividend yield
—
F-score
n/a
Altman Z
−0.06
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(78.63%) (167.75%) (176.92%) (112.14%)
ROA
(63.33%) (111.59%) (158.03%) (97.08%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(42.38%) (76.42%) (88.91%) (102.34%)
Average Days of Receivables
— 0.00 0.00 —
Free Cash Flow per Share
(1.47) (6.95) (2.33) (2.35)
Free Cash Flow
(24.36) (72.42) (70.68) (71.85)
Other line items

Show all line items

Columns are period end dates